ERBB2 and breast cancer: In HER2+ breast cancer cell lines mutated for PIK3CA, as well as in patient-derived xenograft models, MEN1611 seemed to act synergistically when associated with trastuzumab, also inducing a dose-dependent p110α protein depletion and a pro-inflammatory phenotype compatible with p110γ inhibition [103].